The novel SARS-CoV-2 (COVID-19) became a pandemic on 11 March 2020. The epidemiological picture is constantly evolving, and on 13 May, 4,170,424 cases and 287,399 confirmed deaths have been reported (WHO Report). People with COVID-19 infection may show several symptoms, including fever, cough, nausea, vomiting, dyspnea, myalgia, fatigue, arthralgia, headache, diarrhea, and rarely arthritis [1]. COVID-19 clinical features range from asymptomatic patients to acute respiratory distress syndrome (ARDS) and multiple organ dysfunction [2, 3]. Influenza symptoms are associated with a cascade of inflammatory mediators. Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF- α) levels in plasma and upper respiratory secretions directly correlate with the magnitude of viral replication, fever, and respiratory and systemic symptoms, including musculoskeletal clinical manifestations [4, 5] Musculoskeletal symptoms such as fatigue, myalgia and arthralgia are common COVID-19 symptoms, but their prevalence has not yet been systematically investigated [6, 7]. We collected the published clinical data of the past 5 months to ascertain the prevalence of musculoskeletal symptoms and epidemiological characteristics published worldwide in COVID-19 patients.
Data were tabulated using Microsoft ExcelTM 2020 V.16.34. The value was showed as mean ± SD. Student t test was used to reveal musculoskeletal symptoms between the total sample. To assess the incidence for each clinical variable, frequency analysis was performed. Regression analysis (R2) was used to examine correlations between the total sample and musculoskeletal symptoms extracted. The level of significant was set at p < 0.05.
The relevant reference and the data collected from the included articles are indicated in Tables 1 and 2.
Table 1.
Demographics
| Study (year) | No. of patients | Sex | Age (mean SD or median IQR) | Study design | Country |
|---|---|---|---|---|---|
| Zheng et al. [8] | 99 |
M 51 F 48 |
49.40 (SD 18.45) | Retrospective single center | China |
| Lei et al. [9] | 34 |
M 14 F 20 |
55 (43–63) | Retrospective single center | China |
| Mo et al. [10] | 155 |
M 86 F 69 |
54 (42–66) | Retrospective single center | China |
| Qian et al. [11] | 91 |
M 37 F 54 |
50 (54–80) | Retrospective multi-center | China |
| Ma et al. [12] | 37 |
M 20 F 17 |
62 (59–70) | Retrospective single center | China |
| Jin et al. [13] | 651 |
M 331 F 246 |
46.0 (32–60) | Retrospective multi-center | China |
| Zheng et al. [14] | 161 |
M 80 F 81 |
45.0 (33.5–57) | Retrospective single center | China |
| Wang et al. [15] | 80 |
M 31 F 49 |
39.0 (32–48.5) | Retrospective multi-center (electronic database) | China |
| Chen et al. [16] | 203 |
M 108 F 95 |
54.0 (20–91) | Retrospective single center | China |
| Zhou et al. [17] | 21 |
M 13 F 8 |
66.1 (SD 13.94) | Retrospective single center | China |
| Lo et al. [18] | 10 |
M 3 F 7 |
54 (27–64) | Retrospective single center | China |
| Huang et al. [19] | 41 |
M 30 F 11 |
49.0 (41.0–58.0) | Prospective multi-center (electronic database) | China |
| Zhang et al. [20] | 645 |
M 328 F 317 |
46.65 (SD 13.82) | Retrospective multi-center (electronic database) | China |
| Chen et al. [21] | 249 |
M 126 F 123 |
51.0 (36–64) | Retrospective single center | China |
| Feng et al. [22] | 476 |
M 271 F 205 |
53.0 (40–64) | Retrospective multi-center | China |
| Chen et al. [23] | 274 |
M 171 F 103 |
62.0 (44–70) | Retrospective single center | China |
| Zhang et al. [24] | 140 |
M 71 F 69 |
57.0 (25–87) | Retrospective multi-center | China |
| Lian et al. [25] | 788 |
M 407 F 381 |
41.15 (SD 11.38) | Retrospective multi-center (electronic database) | China |
| Cai et al. [26] | 298 |
M 145 F 153 |
47.5 (33–61) | Retrospective single center | China |
| Wan et al. [27] | 135 |
M 72 F 63 |
47.0 (36–55) | Retrospective single center | China |
| Cao et al. [28] | 102 |
M 53 F 49 |
54.0 (37–67) | Retrospective single center | China |
| Wang et al. [29] | 339 |
M 166 F 173 |
69.0 (65–76) | Retrospective single center | China |
| Xu et al. [30] | 62 |
M 36 F 27 |
41.0 (32–52) | Retrospective single center | China |
| Zhou et al. [31] | 191 |
M 119 F 72 |
56.0 (46–67) | Retrospective multi-center cohort study | China |
| Wu et al. [32] | 201 |
M 128 F 73 |
51.0 (43–60) | Retrospective single center cohort study | China |
| Du et al. [33] | 85 |
M 62 F 23 |
65.8 | Retrospective multi-center | China |
| Wang et al. [34] | 69 |
M 32 F 37 |
42.0 (35–62) | Retrospective single center | China |
| Guan et al. [35] | 1099 |
M 640 F 459 |
47.0 (35–58) | Retrospective multi-center | China |
| Goyal et al. [36] | 393 |
M 238 F 155 |
62.2 (49–74) | Retrospective multi-center | USA |
| Zhang et al. [37] | 28 |
M 17 F 11 |
65.0 (56–70) | Retrospective single center | China |
| Chen et al. [38] | 118 |
M 0 F 118 |
31.0 (28–34) | Retrospective single center | China |
| Wang et al. [39] | 1012 |
M 524 F 488 |
50.0 (39–58) | Retrospective multi-center | China |
| Xia et al. [40] | 10 |
M 6 F 4 |
56.5 | Retrospective single center | China |
| Liang et al. [41] | 1590 |
M 904 F 674 |
48.9 (SD 16.3) | Retrospective multi-center | China |
| Dai et al. [42] | 234 |
M 136 F 98 |
44.6 | Retrospective single center | China |
| Li et al. [43] | 25 |
M 12 F 13 |
45.6 | Retrospective single center | China |
| Chu et al. [44] | 54 |
M 36 F 18 |
39 | Retrospective single center | China |
| Qi et al. [45] | 70 |
M 39 F 31 |
39.5 | Retrospective multi-center | China |
| Godaert et al. [46] | 17 |
M 8 F 9 |
86.5 | Retrospective single center | France |
| Ye et al. [47] | 5 |
M 2 F 3 |
30.0 | Retrospective single center | China |
| Huang et al. [48] | 22 |
M 6 F 16 |
22.0 (16.0–23.0) | Retrospective single center | China |
| Tian et al. [49] | 262 |
M 127 F 135 |
47.5 | Retrospective single center | China |
| Huang et al. [50] | 34 |
M 14 F 20 |
56.2 | Retrospective single center | China |
| Xia et al. [51] | 20 |
M 13 F 7 |
1.5 | Retrospective single center | China |
| Zhao et al. [52] | 101 |
M 56 F 45 |
44.44 | Retrospective multi-center | China |
| Xu et al. [53] | 51 |
M 25 F 26 |
41.6 | Retrospective single center | China |
| Li et al. [54] | 548 |
M 279 F 269 |
60.0 (48–69) | Retrospective single center | China |
| Xu et al. [55] | 90 |
M 39 F 51 |
50.0 (18–86) | Retrospective single center | China |
| Lei et al. [56] | 119 |
M 77 F 42 |
49.0 (SD 13.6) | Retrospective multi-center | China |
| Pung et al. [57] | 17 |
M 7 F 10 |
40.0 | Retrospective single center | Singapore |
| Xu et al. [71] | 50 |
M 29 F 21 |
42.3 | Retrospective single center | China |
| Escalera-Antezana et al. [58] | 12 |
M 6 F 6 |
36.5 | Retrospective single center | Bolivia |
| Lechien et al. [59] | 417 |
M 154 F 263 |
36.9 (SD 11.4) | Retrospective multi-center | Europe |
| Dong et al. [72] | 11 |
M 5 F 6 |
40.3 | Retrospective single center | China |
| Total: 54 | 12.046 |
M 6427 (54%) F 5597 (46%) |
52.13 |
Table 2.
Musculoskeletal symptoms
| Study (year) | No. of patients | Fatigue (nr/%) | Arthralgia/Myalgia (nr/%) |
|---|---|---|---|
| Zheng et al. [37] | 99 | 72 (73%) | 12 (12%) |
| Lei et al. [36] | 34 | 25 (73.5%) | 11 (32.4%) |
| Mo et al. [60] | 155 | 60 (73.2) | 50 (61.0%) |
| Qian et al. [61] | 91 | 40 (43.96%) | 5 (5.49%) |
| Ma et al. [62] | 37 | 4 (10.8%) | 4 (10.8%) |
| Jin et al. [10] | 651 | 119 (18.2%) | / |
| Zheng et al. [11] | 161 | 64 (39.8%) | 18 (11.2%) |
| Wang et al. [12] | 80 | 28 (35%) | 19 (23.75%) |
| Chen et al. [13] | 203 | 16 (7.9%) | 54 (26.6) |
| Zhou et al. [14] | 21 | 5 (23.8%) | 2 (9.5%) |
| Lo et al. [15] | 10 | / | 3 (30%) |
| Huang et al. [16] | 41 | 18 (44%) | / |
| Zhang et al. [17] | 645 | 118 (18.3%) | 71 (11%) |
| Chen et al. [18] | 249 | 39 (15.7%) | / |
| Feng et al. [19] | 476 | / | 59 (12.4%) |
| Chen et al. [20] | 274 | 137 (50%) | 60 (22%) |
| Zhang et al. [58] | 140 | 105 (75%) | / |
| Lian et al. [47] | 788 | 139 (17.6%) | 91 (11.5%) |
| Cai et al. [21] | 298 | 13 (4.3%) | / |
| Wan et al. [22] | 135 | / | 44 (32.5%) |
| Cao et al. [9] | 102 | 56 (54.9%) | 35 (34.3) |
| Wang et al. [32] | 339 | 135 (39.9%) | 16 (4.7%) |
| Xu et al. [26] | 62 | / | 32 (52%) |
| Zhou et al. [27] | 191 | 44 (23%) | 29 (15%) |
| Wu et al. [29] | 201 | 65 (32.3%) | / |
| Du et al. [33] | 85 | 50 (58.8%) | 14 (16.5%) |
| Wang et al. [35] | 69 | 29 (42%) | 21 (30%) |
| Guan et al. [33] | 1099 | 419 (38%) | 164 (15%) |
| Goyal et al. [46] | 393 | / | 94 (24%) |
| Zhang et al. [24] | 28 | 18 (64%) | 4 (14%) |
| Chen et al. [34] | 118 | 19 (16%) | / |
| Wang et al. [41] | 1012 | / | 170 (17%) |
| Xia et al. [38] | 10 | 3 (30%) | / |
| Liang et al. [39] | 1590 | 680 (43%) | 278 (17%) |
| Dai et al. [40] | 234 | 31 (13%) | 21 (9%) |
| Li et al. [41] | 25 | 17 (68%) | / |
| Chu et al. [42] | 54 | 9 (17%) | 3 (6%) |
| Qi et al. [43] | 70 | / | 12 (17%) |
| Godaert et al. [7] | 17 | 10 (59%) | / |
| Ye et al. [28] | 5 | 5 (100%) | / |
| Huang et al. [44] | 22 | 5 (23%) | 4 (18%) |
| Tian et al. [45] | 262 | 69 (26%) | / |
| Huang et al. [8] | 34 | / | 22 (65%) |
| Xia et al. [48] | 20 | 1 (5%) | / |
| Zhao et al. [49] | 101 | / | 17 (17%) |
| Xu et al. [25] | 51 | 2 (4%) | 8 (16%) |
| Li et al. [51] | 548 | 258 (47%) | 111 (20%) |
| Xu et al. [52] | 90 | 19 (21%) | 25 (28%) |
| Lei et al. [54] | 119 | / | 18 (15%) |
| Pung et al. [6] | 17 | / | 5 (29%) |
| Xu et al. [55] | 50 | 8 (16%) | 8 (16%) |
| Escalera-Antezana et al. [59] | 12 | / | 5 (42%) |
| Lechien et al. [57] | 417 | 129 (31%) | 246 (59%) |
| Dong et al. [56] | 11 | 2 (18%) | 1 (9%) |
| Total: 54 | Tot: 12,046 | 3085 (25.6%) | 1866 (15.5%) |
Data on 12,046 patients (54% male and 46% females) were available. The number of patients in the selected studies ranged from 5 to 1590 patients (223 ± 312 patients). The sex ratio (male to female) was 1:15, and the overall average of patients was 52.13 years. The majority of the studies arose from China, mainly from Wuhan; one was from Singapore [57], two from Europe [46, 59], one from the USA [36], and one from Bolivia [58]. Musculoskeletal symptoms were present from the earliest stage of the viral illness and were reported in patients necessitating intensive care in the end stage of the condition. The total prevalence of fatigue symptom was 25.6% (R2 =0.56; p value = 0.004), while the prevalence of arthralgia and/or myalgia was 15.5% (R2 = 0.66; p value = 0.001; Fig. 1).
Fig. 1.
Relationships of fatigue and arthralgia/myalgia on all patients
Eight studies reported a prevalence higher than 50% of patients with fatigue [8, 9, 24, 25, 28, 37, 46, 47], while three studies reported higher values for arthralgia/myalgia symptoms [50, 53, 59]. The prevalence of musculoskeletal symptoms in studies from Europe reached high values [46, 59]; Lechien et al., for example, reported on 417 COVID-19 patients from 12 European hospitals and found myalgia in 246 (59%) and arthralgia in 129 (31%) of these patients [59].
Clinical presentation of COVID-19 ranges from absence of symptoms to severe pneumonia. Fever, dry cough and fatigue are common symptoms, as indeed are myalgia and arthralgia [6, 53]. Most of the articles are retrospective single center studies: data were collected in a non-homogeneous way, especially regarding comorbidities, lifestyle habits, and severity of the illness. Based on our work, we cannot state, for example, whether children and younger patients less commonly present musculoskeletal symptoms at onset [63]. Most studies originate from China, which is not surprising, and it is not clear whether the prevalence of musculoskeletal symptoms at onset is influenced by socio-geographical factors [64]. The most common symptoms in patients with mild to moderate clinical presentation of the condition are fever, fatigue, and dry cough, followed by other symptoms including headache, nasal congestion, sore throat, myalgia, and arthralgia [65, 66].
The evidence on the central role of inflammation during COVID-19 infection underlines the need to block this inflammatory cascade [30, 60–62, 67–70]. The presence of musculoskeletal symptoms is worrying: there is a high rate of use, especially in the middle age and elderly population, of NSAIDs. The fact that patients therefore report musculoskeletal symptoms is even more worrying because it may imply that the inflammatory reactions overcome the anti-inflammatory effect of such drugs.
Clinical features have to be analyzed deeply, especially considering the new evidences on COVID-19. Musculoskeletal symptoms should be married with laboratory findings, such as inflammatory and infection-related parameters (Interleukin-6, Procalcitonin, C-reactive protein). Understandably, the involvement of the musculoskeletal system has not been deeply investigated during this pandemic, but synovial and muscle biopsy, and joint fluid analysis, for example, should clarify how extensive the attack of the virus on the whole of the human body is. Until now, no report has been published on the presence of COVID-19 in the skeletal muscles, joint, or bones. The musculoskeletal symptoms are only anecdotally attributed to indirect effects, mainly arising from inflammatory and/or immune response, but other mechanisms can be hypothesized, such as direct damage by the virus on the endothelium or peripheral nerves. These findings could help to plan specific rehabilitation protocols in COVID-19 patients.
As a new infectious disease, it is particularly important to underline the clinical features of COVID-19, especially in the early stage of the illness, to help clinicians to individuate and isolate patients earlier, and then minimize its diffusion. From the onset of the symptoms and to the most severe stages of COVID-19 disease, musculoskeletal symptoms, including myalgia, arthralgia, and fatigue, are a nearly constant presence. It is still unclear how the effects of COVID-19 on the musculoskeletal system are mediated.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Lucio Cipollaro, Email: lcipollaro@unisa.it.
Lorenzo Giordano, Email: lgdm89@gmail.com.
Johnny Padulo, Email: johnny.padulo@unimi.it.
Francesco Oliva, Email: olivafrancesco@hotmail.com.
Nicola Maffulli, Email: n.maffulli@qmul.ac.uk.
References
- 1.Park M, Cook AR, Lim JT, et al. A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med. 2020;9. 10.3390/jcm9040967. [DOI] [PMC free article] [PubMed]
- 2.Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect Published Online First: 10 April 2020. doi:10.1016/j.jinf.2020.03.041. [DOI] [PMC free article] [PubMed]
- 3.Zhu Z, Cai T, Fan L, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis Published Online First: 22 April 2020. doi:10.1016/j.ijid.2020.04.041. [DOI] [PMC free article] [PubMed]
- 4.Kaiser L, Fritz RS, Straus SE, et al. Symptom pathogenesis during acute influenza: interleukin-6 and other cytokine responses. J Med Virol. 2001;64:262–268. doi: 10.1002/jmv.1045. [DOI] [PubMed] [Google Scholar]
- 5.Misra DP, Agarwal V, Gasparyan AY, et al. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol Published Online First: 10 April 2020. doi:10.1007/s10067-020-05073-9. [DOI] [PMC free article] [PubMed]
- 6.Pung R, Chiew CJ, Young BE, et al. Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures. Lancet. 2020;395:1039–1046. doi: 10.1016/S0140-6736(20)30528-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Godaert L, Proye E, Demoustier-Tampere D, et al. Clinical characteristics of older patients: the experience of a geriatric short-stay unit dedicated to patients with COVID-19 in France. J Infect Published Online First: 17 April 2020. doi:10.1016/j.jinf.2020.04.009. [DOI] [PMC free article] [PubMed]
- 8.Huang Y, Tu M, Wang S, et al. Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis. Travel Med Infect Dis 2020;101606. doi:10.1016/j.tmaid.2020.101606. [DOI] [PMC free article] [PubMed]
- 9.Cao J, Tu W-J, Cheng W, et al. Clinical features and short-term outcomes of 102 patients with Corona Virus Disease 2019 in Wuhan, China. Clin Infect Dis Published Online First: 2 April 2020. doi:10.1093/cid/ciaa243. [DOI] [PMC free article] [PubMed]
- 10.Jin X, Lian J-S, Hu J-H, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut Published Online First: 24 March 2020. doi:10.1136/gutjnl-2020-320926. [DOI] [PMC free article] [PubMed]
- 11.Zheng F, Tang W, Li H, et al. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci. 2020;24:3404–3410. doi: 10.26355/eurrev_202003_20711. [DOI] [PubMed] [Google Scholar]
- 12.Wang X, Liu W, Zhao J, et al. Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan, China. J Hosp Infect Published Online First: 14 April 2020. doi:10.1016/j.jhin.2020.04.019. [DOI] [PMC free article] [PubMed]
- 13.Chen T, Dai Z, Mo P, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol A Biol Sci Med Sci Published Online First: 11 April 2020. doi:10.1093/gerona/glaa089. [DOI] [PMC free article] [PubMed]
- 14.Zhou Y, Han T, Chen J, et al. Clinical and autoimmune characteristics of severe and critical cases with COVID-19. Clin Transl Sci Published Online First: 21 April 2020. doi:10.1111/cts.12805. [DOI] [PMC free article] [PubMed]
- 15.Lo IL, Lio CF, Cheong HH, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci. 2020;16:1698–1707. doi: 10.7150/ijbs.45357. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Zhang X, Cai H, Hu J, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis. 2020;94:81–87. doi: 10.1016/j.ijid.2020.03.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Chen J, Qi T, Liu L, et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect. 2020;80:e1–e6. doi: 10.1016/j.jinf.2020.03.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Feng Y, Ling Y, Bai T, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med Published Online First: 10 April y. doi:10.1164/rccm.202002-0445OC.
- 20.Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy Published Online First: 2 April 2020. doi:10.1111/all.14309. [DOI] [PubMed]
- 22.Wan S, Xiang Y, Fang W, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol Published Online First: 21 March 2020. doi:10.1002/jmv.25783. [DOI] [PMC free article] [PubMed]
- 23.Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect Published Online First: 30 March y. doi:10.1016/j.jinf.2020.03.019. [DOI] [PMC free article] [PubMed]
- 24.Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol Published Online First: 26 March 2020. doi:10.1016/j.annonc.2020.03.296. [DOI] [PMC free article] [PubMed]
- 25.Xu T, Chen C, Zhu Z, et al. Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. Int J Infect Dis. 2020;94:68–71. doi: 10.1016/j.ijid.2020.03.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Xu X-W, Wu X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi: 10.1136/bmj.m606. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Ye F, Xu S, Rong Z, et al. Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster. Int J Infect Dis. 2020;94:133–138. doi: 10.1016/j.ijid.2020.03.042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med Published Online First: 13 March 2020. doi:10.1001/jamainternmed.2020.0994. [DOI] [PMC free article] [PubMed]
- 30.Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta. 2020;505:190–191. doi: 10.1016/j.cca.2020.03.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med Published Online First: 3 April 2020. doi:10.1164/rccm.202003-0543OC. [DOI] [PMC free article] [PubMed]
- 32.Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis Published Online First: 16 March 2020. doi:10.1093/cid/ciaa272. [DOI] [PMC free article] [PubMed]
- 33.Guan W, Ni Z, Hu Y, et al. Clinical characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine 2020;0:null. doi:10.1056/NEJMoa2002032. [DOI] [PMC free article] [PubMed]
- 34.Chen L, Li Q, Zheng D, et al. Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. N Engl J Med Published Online First: 17 April 2020. doi:10.1056/NEJMc2009226. [DOI] [PMC free article] [PubMed]
- 35.Wang X, Fang J, Zhu Y, et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. Clin Microbiol Infect Published Online First: 3 April 2020. doi:10.1016/j.cmi.2020.03.032. [DOI] [PMC free article] [PubMed]
- 36.Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine 2020;:100331. doi:10.1016/j.eclinm.2020.100331. [DOI] [PMC free article] [PubMed]
- 37.Zheng Y, Xu H, Yang M, et al. Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. J Clin Virol. 2020;127:104366. doi: 10.1016/j.jcv.2020.104366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Xia X-Y, Wu J, Liu H-L, et al. Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19. J Clin Virol. 2020;127:104360. doi: 10.1016/j.jcv.2020.104360. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Liang W-H, Guan W-J, Li C-C, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): a nationwide analysis of China. Eur Respir J Published Online First: 8 April 2020. doi:10.1183/13993003.00562-2020. [DOI] [PMC free article] [PubMed]
- 40.Dai H, Zhang X, Xia J, et al. High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu, China. Int J Infect Dis. 2020;95:106–112. doi: 10.1016/j.ijid.2020.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Li X, Wang L, Yan S, et al. Clinical characteristics of 25 death cases with COVID-19: a retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94:128–132. doi: 10.1016/j.ijid.2020.03.053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Chu J, Yang N, Wei Y, et al. Clinical characteristics of 54 medical staff with COVID-19: a retrospective study in a single center in Wuhan, China. J Med Virol Published Online First: 29 March 2020. doi:10.1002/jmv.25793. [DOI] [PMC free article] [PubMed]
- 43.Qi X, Liu C, Jiang Z, et al. Multicenter analysis of clinical characteristics and outcome of COVID-19 patients with liver injury. J Hepatol Published Online First: 16 April 2020. doi:10.1016/j.jhep.2020.04.010.
- 44.Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study. J Infect Published Online First: 10 April 2020. doi:10.1016/j.jinf.2020.03.006. [DOI] [PMC free article] [PubMed]
- 45.Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020;80:401–406. doi: 10.1016/j.jinf.2020.02.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med Published Online First: 17 April 2020. doi:10.1056/NEJMc2010419. [DOI] [PMC free article] [PubMed]
- 47.Lian J, Jin X, Hao S, et al. Analysis of epidemiological and clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis Published Online First: 25 March 2020. doi:10.1093/cid/ciaa242. [DOI] [PMC free article] [PubMed]
- 48.Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020;55:1169–1174. doi: 10.1002/ppul.24718. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Zhao W, Zhong Z, Xie X, et al. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol. 2020;214:1072–1077. doi: 10.2214/AJR.20.22976. [DOI] [PubMed] [Google Scholar]
- 50.Vetter P, Vu DL, L’Huillier AG, et al. Clinical features of covid-19. BMJ. 2020;369. 10.1136/bmj.m1470. [DOI] [PubMed]
- 51.Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol Published Online First: 12 April 2020. doi:10.1016/j.jaci.2020.04.006. [DOI] [PMC free article] [PubMed]
- 52.Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020;47:1275–1280. doi: 10.1007/s00259-020-04735-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Cruz AT, Zeichner SL. COVID-19 in children: initial characterization of the pediatric disease. Pediatrics Published Online First: 16 March 2020. doi:10.1542/peds.2020-0834. [DOI] [PubMed]
- 54.Lei Z, Cao H, Jie Y, et al. A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China. Travel Med Infect Dis 2020;:101664. doi:10.1016/j.tmaid.2020.101664. [DOI] [PMC free article] [PubMed]
- 55.Xu Y-H, Dong J-H, An W-M, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect. 2020;80:394–400. doi: 10.1016/j.jinf.2020.02.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Dong X, Cao Y-Y, Lu X-X, et al. Eleven faces of coronavirus disease 2019. Allergy Published Online First: 20 March 2020. doi:10.1111/all.14289. [DOI] [PMC free article] [PubMed]
- 57.Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol Published Online First: 6 April 2020. doi:10.1007/s00405-020-05965-1. [DOI] [PMC free article] [PubMed]
- 58.Zhang J-J, Dong X, Cao Y-Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy Published Online First: 19 February 2020. doi:10.1111/all.14238. [DOI] [PubMed]
- 59.Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, et al. Clinical features of the first cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain. Travel Med Infect Dis 2020;:101653. doi:10.1016/j.tmaid.2020.101653. [DOI] [PMC free article] [PubMed]
- 60.Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis Published Online First: 16 March 2020. doi:10.1093/cid/ciaa270.
- 61.Qian G-Q, Yang N-B, Ding F, et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. QJM Published Online First: 17 March 2020. doi:10.1093/qjmed/hcaa089. [DOI] [PMC free article] [PubMed]
- 62.Ma J, Yin J, Qian Y, et al. Clinical characteristics and prognosis in cancer patients with COVID-19: a single center’s retrospective study. J Infect Published Online First: 14 April 2020. doi:10.1016/j.jinf.2020.04.006. [DOI] [PMC free article] [PubMed]
- 63.Wang C, Pan R, Wan X, et al. Immediate psychological responses and associated factors during the initial stage of the 2019 Coronavirus Disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health 2020;17. doi:10.3390/ijerph17051729. [DOI] [PMC free article] [PubMed]
- 64.Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med Published Online First: 24 February 2020. 10.1016/S2213-2600(20)30079-5. [DOI] [PMC free article] [PubMed]
- 66.Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Sig Transduct Target Ther. 2020;5:1–3. doi: 10.1038/s41392-020-0127-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Fang X, Mei Q, Yang T, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect Published Online First: 11 April 2020. doi:10.1016/j.jinf.2020.03.039. [DOI] [PMC free article] [PubMed]
- 68.Gerlach H. Agents to reduce cytokine storm. F1000Res. 2016;5:2909. doi: 10.12688/f1000research.9092.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. doi: 10.1016/S0140-6736(20)30628-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Ritchie AI, Singanayagam A. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet. 2020;395:1111. doi: 10.1016/S0140-6736(20)30691-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Xu Y-H, Dong J-H, An W-M, Lv XY, Yin XP, Zhang JZ, Dong L, Ma X, Zhang HJ, Gao BL. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect. 2020;80:394–400. 10.1016/j.jinf.2020.02.017. [DOI] [PMC free article] [PubMed]
- 72.Dong X, Cao YY, Lu XX, Zhang JJ, Du H, Yan YQ, Akdis CA, Gao YD. Eleven faces of coronavirus disease 2019. Allergy. 2020. 10.1111/all.14289. [Epub ahead of print]. [DOI] [PMC free article] [PubMed]